title: Cord blood transplant for acute myeloid leukaemia.
abstract: Umbilical cord blood is a haematopoietic progenitor cell source for patients with acute myeloid leukaemia (AML), other haematological malignancies and metabolic diseases who can be cured by allogeneic haematopoietic cell transplantation, but who do not have a human leucocyte antigen compatible related or unrelated donor. Although the first cord blood transplants were done in children, there are currently more cord blood transplants performed in adults. In this review, we explore the history of umbilical cord blood transplantation, paediatric and adult outcome results, and novel trends to improve engraftment and reduce infection. Umbilical cord blood transplantation cures approximately 30-40% of adults and 60-70% of children with AML. Controversial issues, including the use of double versus single cord blood units for transplantation, optimal cord blood unit selection, infection prophylaxis, conditioning regimens and graft versus host disease prophylaxis, will be reviewed. Finally, comparison to other graft sources, cost, access to care, and the ideal graft source are discussed.
authors.affiliation: Division of Hematology/Oncology, Massachusetts General Hospital, Boston, MA, USA.
authors.forename: Karen K
authors.initials: KK
authors.lastname: Ballen
authors.affiliation: Seidman Cancer Center, Case Western Reserve University, Cleveland, OH, USA.
authors.forename: Hillard
authors.initials: H
authors.lastname: Lazarus
mesh_terms: D000328:Adult; D064591:Allografts; D036101:Cord Blood Stem Cell Transplantation; D006086:Graft vs Host Disease / Q000473:pathology / Q000517:prevention & control*; D006801:Humans; D007223:Infant; D015470:Leukemia, Myeloid, Acute / Q000473:pathology / Q000628:therapy*; D061349:Unrelated Donors
keywords: allogeneic haematopoietic cell transplantation; umbilical cord blood